Biotech · Private company
EVIVE Biotechnology
Track this companyFree. Adds EVIVE Biotechnology to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- F-627Phase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- NeulastaPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- F-652Phase 2 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- Recombinant Human Interleukin-22 IgG2-Fc (F-652)Phase 2 · Acute Graft vs Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Systemic CorticosteroidsPhase 2 · Acute Graft vs Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19PHASE2 · TERMINATED · started Jan 26, 2021ClinicalTrials.gov NCT04498377 · fetched Nov 12, 2026
- Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyPHASE3 · COMPLETED · started Apr 12, 2018ClinicalTrials.gov NCT03252431 · fetched Nov 12, 2026
- Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyPHASE3 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02872103 · fetched Nov 12, 2026
- Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHDPHASE1_PHASE2 · COMPLETED · started May 12, 2016ClinicalTrials.gov NCT02406651 · fetched Nov 12, 2026